Ensysce Biosciences, Inc. (ENSCW)
2025-06-30 | ||||
|---|---|---|---|---|
| Federal grants | 1,371,438 | |||
| Research and development | 1,923,430 | |||
| General and administrative | 1,198,523 | |||
| Total operating expenses | 3,121,953 | |||
| Loss from operations | -1,750,515 | |||
| Other income and expense, net | 21,011 | |||
| Interest expense, net | 3,160 | |||
| Change in fair value of liability classified warrants | -853 | |||
| Total other income (expense), net | 16,998 | |||
| Net loss | -1,733,517 | |||
| Net loss attributable to noncontrolling interests | -166 | |||
| Deemed dividend related to warrants down round provision | - | |||
| Net loss attributable to common stockholders | -1,733,351 | |||
| Net income (loss) per share attributable to common stockholders, basic | -0.79 | |||
| Net income (loss) per share attributable to common stockholders, diluted | -0.79 | |||
| Weighted average common shares outstanding, basic | 2,202,299 | |||
| Weighted average common shares outstanding, diluted | 2,202,299 | |||